ames Egan has been a life sciences executive since 1984. As international counsel at Abbott Laboratories and as a Business Development executive at G. D. Searle & Co., Jamie facilitated over two dozen transnational licensing transactions, including regional rights to Celebrex®(celecoxib), and Biaxin®(clarithromycin), and global rights to PREZISTA®(darunavir). As a C level biotech executive Jamie participated in the management and financing of start-up companies in the US, Switzerland and New Zealand. At Idenix he facilitated a transformational regional deal that enabled C-round financing and then executed a $2.9 billion strategic alliance with Novartis that enabled the company’s successful IPO in 2003. Idenix was acquired by Merck for $3.9 billion in 2014. As CBO at ESBATech Jamie facilitated its acquisition in 2009 by Novartis/Alcon for $589 million. Jamie was COO of Sucampo Pharmaceuticals (NASDAQ: SCMP) from 2009 to 2013. He now consults for start-ups with first-in-class/best-in-class programs, and coordinates an investor group that invests in biotechs that seek to execute transformational deals.

 Life sciences